share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 13 16:07
Summary by Moomoo AI
RedHill Biopharma Ltd. has announced an extraordinary general meeting of shareholders to be held on March 20, 2024. The primary agenda for the meeting is to seek approval for an increase in the company's authorized share capital. The meeting will take place at the company's offices in Tel Aviv, Israel. Shareholders of record as of February 19, 2024, will be entitled to vote at the meeting. The Board of Directors has recommended a vote in favor of the proposal. Shareholders are urged to submit their proxies ahead of the meeting to ensure their shares are represented, with the option to revoke the proxy at any time before its exercise. The company has also provided a provision for shareholders to submit written statements...Show More
RedHill Biopharma Ltd. has announced an extraordinary general meeting of shareholders to be held on March 20, 2024. The primary agenda for the meeting is to seek approval for an increase in the company's authorized share capital. The meeting will take place at the company's offices in Tel Aviv, Israel. Shareholders of record as of February 19, 2024, will be entitled to vote at the meeting. The Board of Directors has recommended a vote in favor of the proposal. Shareholders are urged to submit their proxies ahead of the meeting to ensure their shares are represented, with the option to revoke the proxy at any time before its exercise. The company has also provided a provision for shareholders to submit written statements regarding their position on the agenda item by March 10, 2024. If a quorum is not present within half an hour of the appointed time, the meeting will be adjourned to the next business day. All relevant documents and proposed resolutions are available at the company's registered office and on its website, as well as on the SEC's website.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more